David A. Wohl
#165,721
Most Influential Person Now
US infectious disease physician
David A. Wohl's AcademicInfluence.com Rankings
David A. Wohlphilosophy Degrees
Philosophy
#11074
World Rank
#15206
Historical Rank
Logic
#7878
World Rank
#9800
Historical Rank
Download Badge
Philosophy
David A. Wohl's Degrees
- Doctorate Medicine University of California, San Francisco
- Masters Public Health University of California, Berkeley
Why Is David A. Wohl Influential?
(Suggest an Edit or Addition)According to Wikipedia, David Alain Wohl is an American infectious disease physician. During the COVID-19 pandemic, he was among those leading UNC's response to the SARS-CoV-2 pandemic. Wohl was appointed the Medical Director of the COVID Vaccination Clinic at UNC Hospitals Hillsborough Campus and led COVID-19 treatment clinical trials at UNC School of Medicine.
David A. Wohl's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials (2015) (529)
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks (2012) (436)
- Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. (1997) (376)
- Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. (2016) (260)
- Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial (2017) (192)
- Effect of Release from Prison and Re-Incarceration on the Viral Loads of HIV-Infected Individuals (2005) (182)
- All-cause and cause-specific mortality among men released from state prison, 1980-2005. (2008) (180)
- Putting prevention in their pockets: developing mobile phone-based HIV interventions for black men who have sex with men. (2013) (169)
- Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. (2006) (164)
- Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV (2007) (163)
- Molnupiravir, an Oral Antiviral Treatment for COVID-19 (2021) (151)
- Microalbuminuria in HIV infection (2007) (151)
- A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results (2013) (147)
- A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus (2021) (143)
- Intensive Case Management Before and After Prison Release is No More Effective Than Comprehensive Pre-Release Discharge Planning in Linking HIV-Infected Prisoners to Care: A Randomized Trial (2011) (139)
- Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial. (2021) (137)
- Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results (2016) (133)
- Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. (2005) (125)
- Incarceration and Risky Sexual Partnerships in a Southern US City (2007) (115)
- Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults (2014) (114)
- Fish Oil and Fenofibrate for the Treatment of Hypertriglyceridemia in HIV-Infected Subjects on Antiretroviral Therapy: Results of ACTG A5186 (2008) (104)
- The Associations of Regional Adipose Tissue With Lipid and Lipoprotein Levels in HIV-Infected Men (2008) (99)
- A Randomized, Double-Blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Single-Tablet Regimen Efavirenz/Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 144 Results (2014) (99)
- Associations among Race/Ethnicity, ApoC-III Genotypes, and Lipids in HIV-1-Infected Individuals on Antiretroviral Therapy (2006) (96)
- Failure to return for HIV posttest counseling in an STD clinic population. (2003) (84)
- Multilevel challenges to engagement in HIV care after prison release: a theory-informed qualitative study comparing prisoners’ perspectives before and after community reentry (2014) (83)
- Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials (2019) (81)
- Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment Week 144 Results (2017) (79)
- Cytomegalovirus Viremia, Mortality, and End-Organ Disease Among Patients With AIDS Receiving Potent Antiretroviral Therapies (2005) (79)
- Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. (2019) (77)
- Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group. (1999) (77)
- All-cause and cause-specific mortality among black and white North Carolina state prisoners, 1995-2005. (2011) (73)
- Timing and duration of incarceration and high-risk sexual partnerships among African Americans in North Carolina. (2008) (72)
- Regional fat deposition and cardiovascular risk in HIV infection: the FRAM study (2011) (71)
- Metabolic Syndrome Before and After Initiation of Antiretroviral Therapy in Treatment-Naive HIV-Infected Individuals (2012) (68)
- Sexual behaviours of HIV-seropositive men and women following release from prison (2006) (65)
- Personal Protective Equipment: Protecting Health Care Providers in an Ebola Outbreak (2015) (65)
- New filovirus disease classification and nomenclature (2019) (63)
- Adherence to directly observed antiretroviral therapy among human immunodeficiency virus-infected prison inmates. (2003) (62)
- Antiviral Activity, Pharmacokinetics, and Safety of BMS-488043, a Novel Oral Small-Molecule HIV-1 Attachment Inhibitor, in HIV-1-Infected Subjects (2010) (60)
- Dissolution of Primary Intimate Relationships during Incarceration and Implications for Post-release HIV Transmission (2011) (59)
- Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy. (2008) (58)
- Stigma and Ebola survivorship in Liberia: Results from a longitudinal cohort study (2018) (56)
- Dissolution of Primary Intimate Relationships During Incarceration and Associations With Post-Release STI/HIV Risk Behavior in a Southeastern City (2011) (54)
- Characteristics and behaviors associated with HIV infection among inmates in the North Carolina prison system. (2009) (54)
- Testing for HIV, Sexually Transmitted Infections, and Viral Hepatitis in Jails: Still a Missed Opportunity for Public Health and HIV Prevention (2010) (54)
- Remdesivir Treatment in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19): A Comparative Analysis of In-hospital All-cause Mortality in a Large Multicenter Observational Cohort (2021) (53)
- Risk factors for Kaposi's sarcoma among HHV‐8 seropositive homosexual men with AIDS (2005) (51)
- Low Rate of CMV End-Organ Disease in HIV-Infected Patients Despite Low CD4+ Cell Counts and CMV Viremia: Results of ACTG Protocol A5030 (2009) (49)
- Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients (2007) (46)
- Comparison of Cardiovascular Disease Risk Markers in HIV-Infected Patients Receiving Abacavir and Tenofovir: The Nucleoside Inflammation, Coagulation and Endothelial Function (Nice) Study (2014) (43)
- Screening and assessment of coronary heart disease in HIV-infected patients. (2008) (43)
- STAR Study: single tablet regimen emtricitabine/rilpivirine/tenofovir DF is non‐inferior to efavirenz/emtricitabine/tenofovir DF in ART‐naïve adults (2012) (42)
- Epstein-Barr virus and human herpesvirus 8 prevalence in human immunodeficiency virus-associated oral mucosal lesions. (1997) (41)
- Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS: The cytomegalovirus retreatment trial (1996) (41)
- HIV-Infected Prison Inmates: Depression and Implications for Release Back to Communities (2010) (39)
- The Safety of Discontinuation of Maintenance Therapy for Cytomegalovirus (CMV) Retinitis and Incidence of Immune Recovery Uveitis Following Potent Antiretroviral Therapy (2005) (39)
- Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study (2016) (39)
- Surgical Management of HIV-Associated Lipodystrophy: Role of Ultrasonic-Assisted Liposuction and Suction-Assisted Lipectomy in the Treatment of Lipohypertrophy (2007) (38)
- Randomized Controlled Trial of an Intervention to Maintain Suppression of HIV Viremia After Prison Release: The imPACT Trial (2017) (37)
- Decreasing Excess Mortality of HIV-Infected Patients Initiating Antiretroviral Therapy: Comparison with Mortality in General Population in China, 2003–2009 (2013) (37)
- “You're in a World of Chaos”: Experiences Accessing HIV Care and Adhering to Medications After Incarceration (2015) (37)
- Ebola Virus Ribonucleic Acid Detection in Semen More Than Two Years After Resolution of Acute Ebola Virus Infection (2017) (37)
- HIV‐Associated Lipodystrophy Syndrome (2000) (36)
- HIV-Related Research in Correctional Populations: Now is the Time (2011) (36)
- STI/HIV Sexual Risk Behavior and Prevalent STI Among Incarcerated African American Men in Committed Partnerships: The Significance of Poverty, Mood Disorders, and Substance Use (2015) (36)
- Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine (2018) (35)
- Change in Vitamin D Levels and Risk of Severe Vitamin D Deficiency over 48 Weeks among HIV-1-Infected, Treatment-Naive Adults Receiving Rilpivirine or Efavirenz in a Phase III Trial (Echo) (2014) (35)
- Inconsistent reconstitution of cytomegalovirus-specific cell-mediated immunity in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. (2001) (35)
- Baseline cardiovascular risk in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial (2015) (35)
- Attrition among Human Immunodeficiency Virus (HIV)- Infected Patients Initiating Antiretroviral Therapy in China, 2003–2010 (2012) (34)
- Anti–Ebola Virus Antibody Levels in Convalescent Plasma and Viral Load After Plasma Infusion in Patients With Ebola Virus Disease (2018) (33)
- Effect of Cryopreservation on Measurement of Cytomegalovirus‐Specific Cellular Immune Responses in HIV‐infected Patients (2000) (32)
- Confronting Ebola as a Sexually Transmitted Infection. (2016) (32)
- Management of Morphologic Changes Associated With Antiretroviral Use in HIV-Infected Patients (2008) (31)
- Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. (2020) (31)
- Thalidomide in low intermittent doses does not prevent recurrence of human immunodeficiency virus-associated aphthous ulcers. (2001) (30)
- HIV and incarceration: dual epidemics. (2006) (29)
- High household transmission of SARS-CoV-2 in the United States: living density, viral load, and disproportionate impact on communities of color (2021) (29)
- Disease Prevalence and Use of Health Care among a National Sample of Black and White Male State Prisoners (2012) (29)
- Household Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 in the United States: Living Density, Viral Load, and Disproportionate Impact on Communities of Color (2021) (28)
- Efforts at the Frontlines: Implementing a Hepatitis C Testing and Linkage-to-Care Program at the Local Public Health Level (2016) (28)
- Simplification to Abacavir/Lamivudine + Atazanavir Maintains Viral Suppression and Improves Bone and Renal Biomarkers in ASSURE, a Randomized, Open Label, Non-Inferiority Trial (2014) (28)
- An evaluation of HIV testing among inmates in the North Carolina prison system. (2009) (27)
- Cytomegalovirus-specific IFN-γ production is associated with protection against cytomegalovirus reactivation in HIV-infected patients on highly active antiretroviral therapy (2003) (27)
- Opt-out HIV testing in prison: informed and voluntary? (2015) (26)
- Predictors of Repeat Testing and HIV Seroconversion in a Sexually Transmitted Disease Clinic Population (2004) (26)
- Cohort profile: seek, test, treat and retain United States criminal justice cohort (2017) (25)
- Changes in Metabolic Syndrome Status After Initiation of Antiretroviral Therapy (2015) (24)
- Tracking linkage to HIV care for former prisoners (2012) (24)
- The ASSURE study: HIV‐1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir† (2015) (24)
- Underutilization of Statins When Indicated in HIV‐Seropositive and Seronegative Women (2017) (24)
- Risk factors for human herpesvirus 8 seropositivity in the AIDS Cancer Cohort Study. (2006) (23)
- Availability of and Access to Medical Services Among HIV-Infected Inmates Incarcerated in North Carolina County Jails (2004) (23)
- Detection of undiagnosed HIV among state prison entrants. (2013) (23)
- Immunizations in Pediatric and Adult Patients with Inflammatory Bowel Disease: A Practical Case-based Approach (2015) (22)
- Sexuality, sexual practices, and HIV risk among incarcerated African-American women in North Carolina. (2013) (22)
- Absence of Sustained Hyperlactatemia in HIV-Infected Patients With Risk Factors for Mitochondrial Toxicity (2004) (22)
- Total daily pill burden in HIV-infected patients in the southern United States. (2014) (22)
- The Dose Response: Perceptions of People Living with HIV in the United States on Alternatives to Oral Daily Antiretroviral Therapy. (2020) (21)
- Provider Perspectives Regarding the Health Care Needs of a Key Population: HIV‐infected Prisoners After Incarceration (2015) (21)
- Vitamin D deficiency in HIV: a shadow on long-term management? (2014) (21)
- Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758. (2009) (21)
- "Inside These Fences Is Our Own Little World": Prison-Based HIV Testing and HIV-Related Stigma Among Incarcerated Men and Women. (2016) (20)
- Short communication: initiation of an abacavir-containing regimen in HIV-infected adults is associated with a smaller decrease in inflammation and endothelial activation markers compared to non-abacavir-containing regimens. (2012) (20)
- Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. (2021) (20)
- A pilot study of health beliefs and attitudes concerning measures of antiretroviral adherence among prisoners receiving directly observed antiretroviral therapy. (2006) (20)
- Does HAART Efficacy Translate to Effectiveness? Evidence for a Trial Effect (2011) (19)
- Shifting the Paradigm - Applying Universal Standards of Care to Ebola Virus Disease. (2019) (19)
- Financial Incentives for Adherence to Hepatitis C Virus Clinical Care and Treatment: A Randomized Trial of Two Strategies (2017) (19)
- Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267. (2002) (19)
- Transitions to Care in the Community for Prison Releasees with HIV: a Qualitative Study of Facilitators and Challenges in Two States (2015) (19)
- A randomized, double-blind comparison of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E/C/F) for initial HIV-1 treatment: week 96 results (2016) (18)
- Financial Barriers and Lapses in Treatment and Care of HIV‐Infected Adults in a Southern State in the United States (2017) (18)
- From the “Streets” To “Normal Life”: Assessing the Role of Social Support in Release Planning for HIV-Positive and Substance-Involved Prisoners (2009) (18)
- Validation of the Cepheid GeneXpert for Detecting Ebola Virus in Semen (2016) (18)
- Protecting Healthcare Personnel from Acquiring Ebola Virus Disease (2015) (17)
- Increased Persistence of Initial Treatment for HIV Infection With Modern Antiretroviral Therapy (2017) (17)
- Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody Therapy (2021) (16)
- Medication-Taking Practices of Patients on Antiretroviral HIV Therapy: Control, Power, and Intentionality. (2015) (16)
- Locating the Places People Meet New Sexual Partners in a Southern US City to Inform HIV/STI Prevention and Testing Efforts (2011) (16)
- Antiretroviral therapy: when to start. (2014) (15)
- Fish Oil and Fenofibrate for the Treatment of Hypertriglyceridemia in HIV-Infected Subjects on Antiretroviral Therapy: (2009) (15)
- Hospitalization Rates and Outcomes among Persons Living with HIV in the Southeastern United States, 1996-2016. (2020) (15)
- Guidance for Restarting Inflammatory Bowel Disease Therapy in Patients Who Withheld Immunosuppressant Medications During COVID-19 (2020) (15)
- Participant Perspectives in an HIV Cure-Related Trial Conducted Exclusively in Women in the United States: Results from AIDS Clinical Trials Group (ACTG) 5366. (2020) (15)
- Raltegravir Pharmacokinetics in Treatment-Naive Patients Is Not Influenced by Race: Results from the Raltegravir Early Therapy in African-Americans Living with HIV (REAL) Study (2012) (14)
- Apheresis for collection of Ebola convalescent plasma in Liberia (2017) (14)
- Comparing HIV Case Detection in Prison During Opt-In vs. Opt-Out Testing Policies (2016) (14)
- Borderline Personality Disorder Symptom Severity and Sexually Transmitted Infection and HIV Risk in African American Incarcerated Men (2016) (14)
- Comparison of the Outcomes of Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009–2015 (2017) (13)
- Estimated Impact of Targeted Pre-Exposure Prophylaxis: Strategies for Men Who Have Sex with Men in the United States (2019) (13)
- Worsening of endogenous Candida albicans endophthalmitis during therapy with intravenous lipid complex amphotericin B. (1999) (13)
- Post-Ebola Syndrome Presents With Multiple Overlapping Symptom Clusters: Evidence From an Ongoing Cohort Study in Eastern Sierra Leone (2021) (12)
- Excess apoptosis of mononuclear cells contributes to the depressed cytomegalovirus-specific immunity in HIV-infected patients on HAART. (2004) (12)
- Dissolution of Committed Partnerships during Incarceration and STI/HIV-Related Sexual Risk Behavior after Prison Release among African American Men (2018) (12)
- Effect of Directly Observed Antiretroviral Therapy Compared to Self-Administered Antiretroviral Therapy on Adherence and Virological Outcomes among HIV-Infected Prisoners: A Randomized Controlled Pilot Study (2014) (12)
- Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19 (2022) (12)
- Viral and Symptom Rebound in Untreated COVID-19 Infection (2022) (11)
- Effects of raltegravir combined with tenofovir/emtricitabine on body shape, bone density, and lipids in African-Americans initiating HIV therapy (2015) (11)
- Long-Term Complications of Ebola Virus Disease: Prevalence and Predictors of Major Symptoms and the Role of Inflammation. (2019) (11)
- Diagnosis and management of body morphology changes and lipid abnormalities associated with HIV Infection and its therapies. (2004) (11)
- "My Death Will Not [Be] in Vain": Testimonials from Last Gift Rapid Research Autopsy Study Participants Living with HIV at the End of Life. (2020) (10)
- Estimating HIV Medication Adherence and Persistence: Two Instruments for Clinical and Research Use (2018) (10)
- Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to efavirenz/emtricitabine/tenofovir DF at week 96 in treatment‐naïve HIV‐1‐infected patients (2012) (10)
- Moving Lassa Fever Research and Care Into the 21st Century. (2017) (9)
- Individuals motivated to participate in adherence, care and treatment (imPACT): development of a multi-component intervention to help HIV-infected recently incarcerated individuals link and adhere to HIV care (2016) (9)
- LB2. Safety and Efficacy of Combination SARS-CoV-2 Monoclonal Neutralizing Antibodies (mAb) BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients (2021) (9)
- Hospitalization Rates and Causes among Persons with HIV in the US and Canada, 2005-2015. (2020) (9)
- Regulatory T Cells and the Risk of CMV End-Organ Disease in Patients With AIDS (2014) (9)
- Outpatient Treatment of SARS-CoV-2 Infection to Prevent COVID-19 Progression (2021) (8)
- Drug Use Mediates the Relationship Between Depressive Symptoms and Adherence to ART Among Recently Incarcerated People Living with HIV (2018) (8)
- Medicaid Enrollment among Prison Inmates in a Non-expansion State: Exploring Predisposing, Enabling, and Need Factors Related to Enrollment Pre-incarceration and Post-Release (2018) (8)
- Opt-Out HIV Testing of Inmates in North Carolina Prisons: Factors Associated with not Wanting a Test and not Knowing They Were Tested (2016) (8)
- The Committed Intimate Partnerships of Incarcerated African-American Men: Implications for Sexual HIV Transmission Risk and Prevention Opportunities (2017) (8)
- Correction: Simplification to Abacavir/Lamivudine + Atazanavir Maintains Viral Suppression and Improves Bone and Renal Biomarkers in ASSURE, a Randomized, Open Label, Non-Inferiority Trial (2014) (8)
- LB4. A Phase 3, Randomized, Controlled Clinical Trial of Bictegravir in a Fixed-Dose Combination, B/F/TAF, vs. ABC/DTG/3TC in Treatment-Naïve Adults at Week 96 (2018) (8)
- Burden of respiratory viral infection in persons with human immunodeficiency virus (2020) (7)
- Antiretroviral Activity and Safety of Once-Daily Etravirine in Treatment-Naive HIV-Infected Adults: 48-Week Results (2016) (7)
- HIV and Mass Incarceration (2016) (7)
- Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19 (2021) (7)
- Considering metabolic issues when initiating HIV therapy (2007) (7)
- P099 Renal Safety of Tenofovir Alafenamide in Patients at High Risk of Kidney Disease (2016) (7)
- Diagnosing Primary HIV Infection (2002) (7)
- Low prevalence of antiretroviral resistance among HIV type 1-positive prisoners in the Southeast United States. (2013) (7)
- Outpatient Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Infection to Prevent Coronavirus Disease 2019 Progression (2021) (6)
- Reproductive health sequelae among women who survived Ebola virus disease in Liberia (2019) (5)
- P100 Tenofovir alafenamide (TAF) in a single tablet regimen in initial HIV-1 therapy (2015) (5)
- HIV and Mass Incarceration: Where Infectious Diseases and Social Justice Meet (2016) (5)
- Effectiveness of integrase strand transfer inhibitors among treatment-experienced patients in a clinical setting (2019) (5)
- Routine ophthalmologic screening for cytomegalovirus retinitis in patients with AIDS. (2000) (5)
- Antiretroviral Adherence Following Prison Release in a Randomized Trial of the imPACT Intervention to Maintain Suppression of HIV Viremia (2019) (5)
- Deconstructing Most Recent Antiretroviral Recommendations (2010) (4)
- Inadequate HIV care after incarceration: case closed. (2017) (4)
- Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection (2021) (4)
- Patterns of Mood and Personality Factors and Associations With STI/HIV-Related Drug and Sex Risk Among African American Male Inmates (2017) (4)
- Depression, Executive Dysfunction, and Prior Economic and Social Vulnerability Associations in Incarcerated African American Men (2018) (4)
- COVID-19 symptoms at time of testing and association with positivity among outpatients tested for SARS-CoV-2 (2021) (4)
- Development and Implementation of a COVID-19 Respiratory Diagnostic Center (2020) (4)
- Best practices for identifying men who have sex with men for corrections-based pre-exposure prophylaxis provision (2019) (4)
- Selected CNS Outcomes Among INSTI Antiretrovirals (2017) (3)
- Body shape, lipid, and cardiovascular complications of HIV therapy (2005) (3)
- Resistance in Enterobacterales is higher among people with HIV. (2021) (3)
- Integrated Hepatitis C Testing and Linkage to Care at a Local Health Department Sexually Transmitted Disease Clinic: Determining Essential Resources and Evaluating Outcomes (2017) (3)
- Great Expectations: HIV Risk Behaviors and Misperceptions of Low HIV Risk among Incarcerated Men (2018) (3)
- COVID-19 Symptoms at Presentation and Association with Positivity Among Outpatients Tested for SARS-CoV-2 (2021) (3)
- Editorial comment: correcting facial lipoatrophy has little to do with vanity. (2005) (3)
- Prevalence of HIV Associated Neurocognitive Disorders (HAND) in Virologically Suppressed HIV + Individuals (2012) (3)
- Diagnosing Primary HIV Infection (2001) (3)
- 1288. Bone Safety Outcomes with F/TAF vs. F/TDF for PrEP in the DISCOVER Trial (2019) (3)
- Group sex event participation: a link to STI risk among African-American heterosexual men incarcerated in North Carolina (2017) (3)
- Infectious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Virus in Symptomatic Coronavirus Disease 2019 (COVID-19) Outpatients: Host, Disease, and Viral Correlates. (2021) (3)
- Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS‐CoV‐2 Infection (2022) (2)
- Responding to the Global Threat of High-Consequence Pathogens: Protecting Health Care Workers and Caring for Patients. (2016) (2)
- The impact of semen testing for Ebola virus RNA on sexual behavior of male Ebola survivors in Liberia (2020) (2)
- Infectious SARS-CoV-2 Virus in Symptomatic COVID-19 Outpatients: Host, Disease, and Viral Correlates (2021) (2)
- Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection (2023) (2)
- HIV-Related Sexual Risk among African American Men Preceding Incarceration: Associations with Support from Significant Others, Family, and Friends (2017) (2)
- The efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir DF ('Quad') compared to efavirenz/emtricitabine/tenofovir DF in treatment naive HIV-1 infected subjects: primary results of study GS-US-236-0102 (2012) (2)
- Reduction and persistence of co-circulating respiratory viruses during the SARS-CoV-2 pandemic (2022) (2)
- Clinical Management of Hospitalized Coronavirus Disease 2019 Patients in the United States (2021) (2)
- Spotlight on the Safety Net: Deploying Mobile COVID-19 Testing Programs in North Carolina as an Approach to Improving Health Equity (2021) (2)
- Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir (2018) (2)
- Current and Past Immunodeficiency Are Associated With Higher Hospitalization Rates Among Persons on Virologically Suppressive Antiretroviral Therapy for up to 11 Years. (2021) (2)
- Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial (2022) (2)
- Improving Care for Older Adults with HIV: Identifying Provider Preferences and Priorities (2019) (2)
- Implementing a Prison Medicaid Enrollment Program for Inmates with a Community Inpatient Hospitalization (2018) (2)
- Phase 2 safety and antiviral activity of SAB-185, a novel polyclonal antibody therapy for non-hospitalized adults with COVID-19. (2023) (1)
- Predicting Risk of Multidrug-Resistant Enterobacterales Infections Among People With HIV (2022) (1)
- COVID-19 therapies for inpatients: a review and quality assessment of clinical guidelines (2022) (1)
- Current and Past Immunodeficiency are Associated with Higher Hospitalization Rates among Persons on Virologically Suppressive Antiretroviral Therapy for up to Eleven Years. (2020) (1)
- Predictors of SARS-CoV-2 RNA From Nasopharyngeal Swabs and Concordance With Other Compartments in Nonhospitalized Adults With Mild to Moderate COVID-19 (2022) (1)
- STAR: Rilpivirine/Emtricitabine/TenofovirDF is non-inferior to Efavirenz/Emtricitabine/TenofovirDF in naive adult Latino, black & white subpopulations (2013) (1)
- Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir (2018) (1)
- Risk factors for Kaposi’s sarcoma, non-Hodgkin’s lymphoma, and non-AIDS-defining cancers in the era of highly active anti-retroviral therapy (2005) (1)
- P031: Tenofovir alafenamide in a single-tablet regimen in initial HIV-1 therapy (2015) (1)
- Human Immunodeficiency Virus in the Elderly (2016) (1)
- Diagnosing primary HIV infection. Authors' reply (2002) (1)
- VISION: A Regional Performance Improvement Initiative for HIV Health Care Providers (2014) (1)
- Limb and Trunk Fat Changes by Total Body DEXA After 96 Weeks of Treatment with Once-Daily (QD) Fosamprenavir (FPV) Boosted with either 100 mg or 200 mg of Ritonavir (/r) plus Abacavir (ABC)/Lamivudine(3TC): COL100758 (2008) (1)
- Post-Ebola Symptoms 7 Years after Infection: The natural history of Long Ebola. (2022) (1)
- Non-initiation of hepatitis C virus antiviral therapy in patients with human immunodeficiency virus/hepatitis C virus co-infection. (2016) (1)
- Virological Outcomes of EVG/COBI/FTC/TDF and EVG/COBI/FTC/TAF in Antiretroviral-Naive HIV-1-Infected Participants with Baseline HIV-1 RNA ≥1,000,000 Copies/ml: A Post Hoc Analysis of Phase III Clinical Trials (2018) (1)
- Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2–specific memory T cell responses (2022) (1)
- Two epidemics: incarceration and HIV. How the criminal justice system has played a role in the HIV epidemic. (2012) (1)
- Inequities in access to diagnostics threatens global public health security. (2022) (1)
- SARS-CoV-2 infectious virus, viral RNA in nasopharyngeal swabs, and serostatus of symptomatic COVID-19 outpatients in the United States (2021) (1)
- Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection (2022) (1)
- Recruitment in HIV/AIDS treatment naïve clinical trials in the HAART era - influence of gender, sexual orientation and race (2011) (1)
- Evaluation of a COVID-19 convalescent plasma program at a U.S. academic medical center (2022) (1)
- Screening of genital fluid for Ebola virus. (2017) (1)
- Comparative Effectiveness of Anti-TNF in Combination with Low Dose Methotrexate vs Anti-TNF Monotherapy in Pediatric Crohn's Disease: a Pragmatic Randomized Trial. (2023) (1)
- REGULATORY T CELLS AND THE RISK OF CMV END-ORGAN DISEASE IN AIDS PATIENTS (2014) (1)
- A Rural Health Clinic's Approach to Building a PCMH2 (2015) (0)
- The Clinical Impact of Continuing to Prescribe Antiretroviral Therapy in Patients with Advanced AIDS Who Manifest No Virologic or Immunologic Benefit (2013) (0)
- New filovirus disease classification and nomenclature (2019) (0)
- Antimicrobial-resistant Enterobacterales colonization in people with HIV. (2022) (0)
- The Body: Top Ten Research Reports of 2003 (2004) (0)
- Editorial comment: fish oil to keep the cardiologist away? (2007) (0)
- 91 – Infections staphylococciques (2011) (0)
- The clinical of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no or (2013) (0)
- Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19 (2023) (0)
- Publisher Correction: Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19 (2023) (0)
- 1063. Female sex and SARS-CoV-2 Serostatus Predict Nasopharyngeal RNA Clearance during Early COVID-19 (2022) (0)
- 38. Remdesivir Treatment in Patients Hospitalized with COVID-19: A Comparative Analysis of In-Hospital All-Cause Mortality (2021) (0)
- Statistical Challenges when Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical Trials (2023) (0)
- 878. Association between Anterior Nasal and Plasma SARS-CoV-2 RNA Levels and Hospitalization or Death for Non-Hospitalized Adults with Mild-to-Moderate COVID-19 (2022) (0)
- Viral Blips Were Infrequent in HIV-1-Infected Virologically-Suppressed Adults Treated with Tenofovir Alafenamide or Tenofovir DF Rilpivirine-Containing Regimens (2017) (0)
- Response Letter. (2017) (0)
- Best practices for identifying men who have sex with men for corrections-based pre-exposure prophylaxis provision (2019) (0)
- A systematic review of whether COVID‐19 randomized controlled trials reported on demographic and clinical characteristics (2022) (0)
- Identifying HIV care continuum gaps with verbal autopsy (2018) (0)
- A longitudinal study of olfactory dysfunction and parosmia in mild COVID-19 cases. (2022) (0)
- The Body Pro: HIV JournalView May 2004 (2004) (0)
- Longer-Term Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide Versus Emtricitabine and Tenofovir Disoproxil Fumarate for HIV-1 Pre-Exposure Prophylaxis: Week 96 Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial (2021) (0)
- Infectious Diseases in Travelers (2009) (0)
- Safety and Efficacy of TAF Versus TDF Single-Tablet Regimen in HIV-1 Treatment-Naive Black and Non-Black Patients Through Week 48 (2015) (0)
- Underutilization of HIV Testing Among Men with Incarceration Histories (2019) (0)
- 881. Nasal and Plasma SARS-CoV-2 RNA Levels Predict Timing of Symptom Resolution in the ACTIV-2 Trial of Non-hospitalized Adults with COVID-19 (2022) (0)
- Cardiovascular Biomarkers and Abacavir Therapy (2008) (0)
- Long‐term success for people living with HIV: A framework to guide practice (2023) (0)
- Real-World Insights into Quality Improvement across 11 HIV Clinics in the US (2018) (0)
- Borderline Personality Disorder symptoms and HIV risk behaviors among African-American incarcerated men (2015) (0)
- The Body Pro: HIV JournalView August 2004 (2004) (0)
- Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
- Nasal and Plasma SARS-CoV-2 RNA Levels are Associated with Timing of Symptom Resolution in the ACTIV-2 Trial of Non-hospitalized Adults with COVID-19 (2022) (0)
- 1905. Real-World Insights into Quality Improvement across 11 HIV Clinics in the United States (2018) (0)
- Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
- Hydroxychloroquine for treatment of non‐hospitalized adults with COVID‐19: A meta‐analysis of individual participant data of randomized trials (2023) (0)
- HIV & Hepatitis in the Americas 28–30 April 2016, Mexico City, Mexico (2016) (0)
- POSB12 Association Between Remdesivir Treatment and In-Hospital All-Cause Mortality Among Patients Hospitalized with COVID-19 (2022) (0)
- Patterns of Fat Distribution in HIV-Infected Women (2006) (0)
- 774. Sexual Behaviors and Attitudes of Intimate Partners of Ebola Survivors (2020) (0)
- HIV Antiretroviral Therapy (2014) (0)
- IDCR: Infectious Diseases in Corrections Report (Vol. 9, No. 19, Original version) (2016) (0)
- A prospective, multi-site, cohort study to estimate incidence of infection and disease due to Lassa fever virus in West African countries (the Enable Lassa research programme)–Study protocol (2023) (0)
- 2073. Persistent HIV-1 Viremia Despite Intensive Antiviral Therapy Due to Non-responsive Clonal Viral Lineages (2022) (0)
- HIV Drug Therapy in the Americas Congress, 13 – 15 June 2013, São Paulo, Brazil (2013) (0)
- Changing Regimens: Managing the Successful and Drug Resistant Patient (2014) (0)
- The Body Pro: HIV JournalView February/March 2005 (2005) (0)
- Fostering Self-Management and Patient Activation (2017) (0)
- IDCR: Infectious Diseases in Corrections Report, Vol. 9 No. 11 (2016) (0)
- The persistence of the immune response following Ebola infection in Liberian survivors of the 2014-2015 outbreak (2018) (0)
- Baseline cardiovascular risk in the INSIGHT Strategic Timing of AntiRetroviral Treatment trial (2015) (0)
- It takes more than a machine: A pilot feasibility study of point-of-care HIV-1 viral load testing at a lower-level health center in rural western Uganda (2023) (0)
- Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19 (2023) (0)
- INFECTIOUS DISEASE UPDATE: OUTBREAK MANAGEMENT Editorial 2400 Outbreak Management (2015) (0)
- 2264. The Burden of Respiratory Viral Illness in HIV-Infected Patients (2018) (0)
- The prevalence of Post-Ebola Syndrome hearing loss, Sierra Leone (2022) (0)
- Why we need to re‐define long‐term success for people living with HIV (2023) (0)
- GB Virus C-- Does It Affect HIV Progression ? Two Longitudinal Studies (2004) (0)
- All-CauseandCause-SpecificMortalityAmong MenReleasedFromStatePrison,1980-2005 (2008) (0)
- Top Ten Research Reports of 2003 (2003) (0)
- HIV treatment series. Metabolic complications myths. Some misunderstandings about treatment. (2007) (0)
- HIV Drug Therapy in the Americas 16–18 April 2015, Mexico City, Mexico (2015) (0)
- Reichel's Care of the Elderly: Serious Infections in the Elderly (2009) (0)
- The Impact of Discharge Against Medical Advice on Readmission After Opioid Use Disorder-Associated Infective Endocarditis: a National Cohort Study. (2022) (0)
- 1277. Provider Perspectives on Long-Acting Injectable Antiretroviral Therapy: A “Golden Ticket”? (2022) (0)
- Predicting Risk of Failure Among Those With Low-Level Viremia (2005) (0)
- Family, friend, and significant other support and HIV-related drug and sex risk prior to incarceration among African-American men in prison (2015) (0)
- NC REACH: Creating a Culture of Wellness in Rural HIV Care (2016) (0)
- The Network Navigator's Role: Innovation in HIV Care (2016) (0)
- The Committed Intimate Partnerships of Incarcerated African-American Men: Implications for Sexual HIV Transmission Risk and Prevention Opportunities (2017) (0)
- Standing-up COVID-19 monoclonal antibody infusion centers: Infection prevention and control (2022) (0)
- Racial, ethnic, and gender disparities in hospitalizations among persons with HIV in the United States and Canada, 2005-2015. (2021) (0)
- Dying at Home Due to Coronavirus Disease 2019 (2022) (0)
This paper list is powered by the following services:
Other Resources About David A. Wohl
What Schools Are Affiliated With David A. Wohl?
David A. Wohl is affiliated with the following schools:
